CTI BioPharma to Present at Upcoming June Conferences

Rhea-AI Summary

CTI BioPharma Corp. (NASDAQ: CTIC) announced its participation in two investor conferences in New York City. The presentations are scheduled for the Jefferies Healthcare Conference on June 10, 2022 at 10:00 a.m. ET, and the JMP Securities Life Sciences Conference on June 15, 2022 at 11:00 a.m. ET. Both events will be webcast live and can be accessed through the Investors section of CTI BioPharma's website. The company focuses on developing novel therapies for blood cancers, with its FDA-approved product VONJO™ targeting myelofibrosis.

SEATTLE, June 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in New York City.

Presentation details:

Event: Jefferies Healthcare Conference
Date: Friday, June 10, 2022
Time: 10:00 a.m. ET

Event: JMP Securities Life Sciences Conference
Date: Wednesday, June 15, 2022
Time: 11:00 a.m. ET

Both presentations will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

About CTI BioPharma Corp.
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO™ (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO™ is a trademark of CTI BioPharma Corp.

CTI BioPharma Investor Contacts:

Argot Partners
+212-600-1902
cti@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-upcoming-june-conferences-301560347.html

SOURCE CTI BioPharma Corp.

FAQ

What conferences will CTI BioPharma be presenting at in June 2022?

CTI BioPharma will present at the Jefferies Healthcare Conference on June 10, 2022, and the JMP Securities Life Sciences Conference on June 15, 2022.

What is the timing of CTI BioPharma's presentations at the conferences?

The Jefferies Healthcare Conference presentation is at 10:00 a.m. ET on June 10, 2022, and the JMP Securities Life Sciences Conference is at 11:00 a.m. ET on June 15, 2022.

Where can I watch CTI BioPharma's conference presentations?

CTI BioPharma's presentations will be webcast live and available for replay on their website in the Investors section.

What is VONJO™ and its indication?

VONJO™ is an FDA-approved treatment for adults with intermediate or high-risk myelofibrosis and severe thrombocytopenia.

What is the focus of CTI BioPharma's research?

CTI BioPharma focuses on developing novel targeted therapies for blood-related cancers.